Skip to main content

Gilead Sciences cash flow statement

  • GILD · Nasdaq
  • Biotechnology
  • S&P 500
$168.08+0.08%Close 13 Nov 2026 · Market value $210.1B

In fiscal 2025 (the year to 31 Dec 2025), Gilead Sciences generated $10.02B of operating cash flow and $9.46B of free cash flow, after $563.0M of capital expenditure.

From Gilead Sciences's annual and quarterly reports, each period checked against accounting identities; a figure that does not pass is left blank. Fiscal years follow the company's calendar, the latest ending 31 Dec 2025. TTM is the last four reported quarters added up.

Annual

Gilead Sciences cash flow statement, annual
USDFY 2007FY 2008FY 2009FY 2010FY 2011FY 2012FY 2013FY 2014FY 2015FY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024FY 2025TTM
Net income$1.58B$1.98B$2.64B$2.90B$2.80B$2.59B$3.08B$12.10B$18.11B$13.50B$4.63B$5.46B$5.39B$123.0M$6.22B$4.59B$5.67B$480.0M$8.51B−$3.86B
Depreciation & amortization$36.89M$51.72M$64.56M$127.1M$141.8M$146.1M$103.0M$1.05B$1.10B$1.16B$1.29B$1.43B$1.40B$1.48B$2.03B$2.10B$2.69B$2.77B$2.76B$2.81B
Stock-based compensation$184.6M$153.4M$180.7M$200.0M$192.4M$209.0M$252.0M$360.0M$382.0M$380.0M$638.0M$845.0M$636.0M$643.0M$635.0M$637.0M$766.0M$835.0M$894.0M$913.0M
Operating cash flow$1.67B$2.14B$3.08B$2.83B$3.64B$3.19B$3.10B$12.82B$21.25B$17.05B$11.90B$8.40B$9.14B$8.17B$11.38B$9.07B$8.01B$10.83B$10.02B$14.48B
Operating cash flow margin39.5%40.2%43.9%35.6%43.4%32.9%27.7%51.5%65.1%56.1%45.6%38.0%40.7%33.1%41.7%33.3%29.5%37.7%34.0%46.7%
Capital expenditures$78.65M$115.0M$230.1M$61.88M$131.9M$397.0M$190.0M$557.0M$747.0M$748.0M$590.0M$924.0M$825.0M$650.0M$579.0M$728.0M$585.0M$523.0M$563.0M$699.0M
Acquisitions$46.44M$10.85M$1.25B$91.00M$588.6M$10.75B$379.0M$0.00$0.00$0.00$10.43B$0.00$4.25B$25.92B$1.58B$1.80B$1.15B$4.84B$1.07B$11.95B
Free cash flow$1.59B$2.03B$2.85B$2.77B$3.51B$2.80B$2.92B$12.26B$20.50B$16.30B$11.31B$7.48B$8.32B$7.52B$10.80B$8.34B$7.42B$10.30B$9.46B$13.78B
Free cash flow margin37.6%38.0%40.6%34.9%41.8%28.8%26.0%49.3%62.8%53.6%43.3%33.8%37.1%30.5%39.6%30.6%27.4%35.8%32.1%44.5%
Free cash flow per share$0.82$1.06$1.53$1.59$2.22$1.77$1.72$7.44$13.48$12.00$8.57$5.72$6.51$5.95$8.56$6.61$5.90$8.21$7.53$11.02
Dividends paid——————$0.00$0.00$1.87B$2.46B$2.73B$2.97B$3.22B$3.45B$3.60B$3.71B$3.81B$3.92B$4.00B$4.10B
Gross share repurchases$487.5M$1.97B$998.5M$4.02B$2.38B$667.0M$582.0M$5.35B$10.00B$11.00B$954.0M$2.90B$1.75B$1.58B$546.0M$1.40B$1.00B$1.15B$1.92B$1.37B
Stock issuance proceeds$243.4M$246.1M$222.7M$221.2M$211.7M$466.0M$313.0M$331.0M$319.0M$208.0M$234.0M$289.0M$209.0M$256.0M$169.0M$309.0M$232.0M$422.0M$408.0M$294.0M
Net share repurchases$244.1M$1.72B$775.8M$3.80B$2.17B$201.0M$269.0M$5.02B$9.68B$10.79B$720.0M$2.61B$1.54B$1.33B$377.0M$1.09B$768.0M$728.0M$1.51B$1.08B
Cash interest paid$7.48M$7.39M$8.99M$15.75M$62.18M$249.0M$238.0M$330.0M$529.0M$885.0M$1.04B$1.07B$982.0M$951.0M$979.0M$907.0M$891.0M$951.0M$1.04B—
Free cash flow after SBC$1.41B$1.88B$2.67B$2.57B$3.31B$2.59B$2.66B$11.90B$20.12B$15.92B$10.67B$6.63B$7.68B$6.88B$10.17B$7.71B$6.66B$9.47B$8.56B$12.87B

Quarterly

Gilead Sciences cash flow statement, quarterly
USDQ4 FY2023Q1 FY2024Q2 FY2024Q3 FY2024Q4 FY2024Q1 FY2025Q2 FY2025Q3 FY2025Q4 FY2025Q1 FY2026Q2 FY2026Q3 FY2026
Net income$1.43B−$4.17B$1.61B$1.25B$1.78B$1.31B$1.96B$3.05B$2.18B$2.02B−$10.50B$2.43B
Depreciation & amortization$688.0M$690.0M$694.0M$690.0M$693.0M$696.0M$691.0M$686.0M$687.0M$689.0M$698.0M$740.0M
Stock-based compensation$201.0M$187.0M$210.0M$216.0M$222.0M$209.0M$225.0M$230.0M$230.0M$218.0M$231.0M$234.0M
Operating cash flow$2.17B$2.22B$1.32B$4.31B$2.98B$1.76B$827.0M$4.11B$3.33B$2.54B$3.57B$5.04B
Operating cash flow margin30.5%33.2%19.1%57.1%39.3%26.4%11.7%52.9%42.0%36.6%45.8%60.7%
Capital expenditures$215.0M$105.0M$130.0M$141.0M$147.0M$104.0M$107.0M$147.0M$205.0M$117.0M$140.0M$237.0M
Acquisitions$279.0M$4.04B$152.0M$570.0M$75.00M$273.0M$21.00M$167.0M$609.0M$109.0M$11.21B$19.00M
Free cash flow$1.95B$2.11B$1.20B$4.17B$2.83B$1.65B$720.0M$3.96B$3.12B$2.43B$3.43B$4.80B
Free cash flow margin27.5%31.6%17.2%55.2%37.4%24.8%10.2%51.0%39.4%34.9%44.0%57.8%
Free cash flow per share$1.56$1.70$0.96$3.32$2.21$1.31$0.57$3.16$2.49$1.94$2.76$3.84
Dividends paid$943.0M$990.0M$972.0M$983.0M$973.0M$1.01B$994.0M$1.00B$994.0M$1.04B$1.03B$1.04B
Gross share repurchases$150.0M$400.0M$100.0M$300.0M$350.0M$730.0M$527.0M$435.0M$230.0M$419.0M$355.0M$370.0M
Stock issuance proceeds$26.00M$146.0M$5.00M$98.00M$173.0M$252.0M$27.00M$97.00M$32.00M$166.0M$9.00M$87.00M
Net share repurchases$124.0M$254.0M$95.00M$202.0M$177.0M$478.0M$500.0M$338.0M$198.0M$253.0M$346.0M$283.0M
Free cash flow after SBC$1.75B$1.93B$985.0M$3.95B$2.61B$1.44B$495.0M$3.73B$2.89B$2.21B$3.20B$4.56B

The main figures as JSON and plain text. See data and methodology.

GILD in the terminal

Every line back twenty years, charts of any figure, segments and KPIs by quarter, valuation and alerts.